Clinical Trials Logo

Advanced Esophageal Carcinoma clinical trials

View clinical trials related to Advanced Esophageal Carcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT01486992 Recruiting - Clinical trials for Advanced Esophageal Carcinoma

mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus

Start date: November 2011
Phase: Phase 2
Study type: Interventional

There are few studies about 2nd line treatment in advanced esophageal carcinoma (AEC), some showed that irinotecan may be effective. The investigators previous study has shown the efficacy and safety of paclitaxel/cisplatin as 1st line treatment, so in this phase II study, the investigators would like to observe the efficacy and safety of Nimotuzumab plus Irinotecan/5FU/leucovorin as 2nd line treatment if AEC after failure to 1st treatment of PTX/DDP.

NCT ID: NCT01044420 Recruiting - Clinical trials for Advanced Esophageal Carcinoma

mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial

Start date: May 2009
Phase: Phase 2
Study type: Interventional

There are few studies about 2nd line treatment in advanced esophageal carcinoma(AEC), some showed that irinotecan may be effective. The investigators previous study has shown the efficacy and safety of paclitaxel/cisplatin as 1st line treatment, so in this phase II study, the investigators would like to observe the efficacy and safety of Irinotecan/5FU/leucovorin as 2nd line treatment if AEC after failure to 1st treatment of PTX/DDP.